Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis

Abstract Background Cardiovascular events (CVEs) was considered as one of the primary cause to reduce the quality of life in breast cancer patients with aromatase inhibitors (AIs) treatment, which has not been sufficiently addressed. The aim of this study was to assess the correlation between risk o...

Full description

Bibliographic Details
Main Authors: Yang He, Jianhua Zhang, Guofang Shen, Lin Liu, Qingwei Zhao, Xiaoyang Lu, Hongyu Yang, Dongsheng Hong
Format: Article
Language:English
Published: BMC 2019-10-01
Series:BMC Pharmacology and Toxicology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40360-019-0339-1